Literature DB >> 16385334

Analysis of pain resolution after surgical resection of intramedullary spinal cord cavernous malformations.

Louis J Kim1, Jeffrey D Klopfenstein, Joseph M Zabramski, Volker K H Sonntag, Robert F Spetzler.   

Abstract

OBJECTIVE: To determine the short- and long-term effects of surgical resection of intramedullary spinal cavernous malformations on preoperative pain.
METHODS: Between 1988 and 2003, 53 intramedullary spinal cavernous malformations were surgically managed. A retrospective analysis of this cohort revealed 23 (43%) patients who presented with pain as a clinically relevant feature. Long-term evaluation of pain outcomes was available in 21 patients. Pain outcomes were characterized as improved, unchanged, or worse compared with preoperative and immediate postoperative status.
RESULTS: Seven patients presented with radiculopathy, 12 with central pain, and four with both. Immediately after surgery, pain symptoms improved in 18 (78%) patients, were unchanged in 5 (22%), and were worse in none compared with the patients' preoperative status (n = 23). During the follow-up period, 11 (52%) patients improved, nine (43%) remained at their preoperative baseline, and one (5%) was worse compared with their preoperative levels of pain. The difference in postoperative and long-term pain status was statistically significant (P = 0.031).
CONCLUSION: The surgical efficacy for improving pain related to intramedullary spinal cavernous malformations may be worse than implied in the literature. Although pain relief immediately after surgery is good, we found that recurrence is common and that only approximately 50% of patients report long-term benefit. Despite the significant limitations of this retrospective study, these data may serve as a guide when counseling patients preoperatively to help them to maintain realistic expectations about outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 16385334     DOI: 10.1227/01.neu.0000192161.95893.d7

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Symptomatic spinal cavernous malformations: indication for microsurgical treatment and outcome.

Authors:  Homajoun Maslehaty; Harald Barth; Athanassios K Petridis; Alexandros Doukas; Hubertus Maximilian Mehdorn
Journal:  Eur Spine J       Date:  2011-07-14       Impact factor: 3.134

Review 2.  Enhanced recovery after surgery in intramedullary and extramedullary spinal cord lesions: perioperative considerations and recommendations.

Authors:  Sauson Soldozy; Parantap Patel; Mazin Elsarrag; Pedro Norat; Daniel M Raper; Jennifer D Sokolowski; Kaan Yağmurlu; Min S Park; Petr Tvrdik; M Yashar S Kalani
Journal:  Spinal Cord       Date:  2019-07-29       Impact factor: 2.772

3.  A retrospective and consecutive analysis of the epidemiology and management of spinal cavernomas over the last 20 years in a single center.

Authors:  Ardeshir Ardeshiri; Neriman Özkan; Bixia Chen; Klaus-Peter Stein; Dorothea Miller; Bernd-Otto Hütter; Ibrahim Erol Sandalcioglu; Ulrich Sure
Journal:  Neurosurg Rev       Date:  2015-12-02       Impact factor: 3.042

Review 4.  A systematic review on the outcome of intramedullary spinal cord cavernous malformations.

Authors:  Evridiki Asimakidou; Lieropi Tzanetaki Meszaros; Dimitrios M Anestis; Parmenion P Tsitsopoulos
Journal:  Eur Spine J       Date:  2022-08-06       Impact factor: 2.721

Review 5.  Intramedullary lesions of the conus medullaris: differential diagnosis and surgical management.

Authors:  Florian H Ebner; Florian Roser; Marcus A Acioly; Wolfgang Schoeber; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2008-09-27       Impact factor: 3.042

6.  Intramedullary spinal cord cavernous malformations-association between intraoperative neurophysiological monitoring changes and neurological outcome.

Authors:  Sebastian Niedermeyer; Andrea Szelenyi; Christian Schichor; Joerg-Christian Tonn; Sebastian Siller
Journal:  Acta Neurochir (Wien)       Date:  2022-09-06       Impact factor: 2.816

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.